April, 2019

Publication of the 2018 Registration Document

Paris (France), April 8, 2019 – 5:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced the publication of the Company’s 2018 Registration Document. The 2018 Registration Document, filed with the French Market Authorities (Autorité des Marchés…read more →

Ordinary General Meeting on April 26, 2019

Paris (France), April 5, 2019 – 10 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, announced today that Onxeo’s shareholders are invited to attend the Company’s Ordinary General Meeting which is being held on Friday, April 26, 2019…read more →

Posters – AACR 2019

Molecular analysis of the mechanism of action of AsiDNA™ brings new clues on DNA damage response regulation AsiDNA™, a novel DNA repair inhibitor to radio-sensitize aggressive medulloblastoma subtypes AsiDNA™ abrogates acquired resistance to PARP inhibitors Development of a Biomarker-driven patient selection strategy for AsiDNA™ treatment